Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06030076
Other study ID # SW-ATCH
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 6, 2023
Est. completion date January 2025

Study information

Verified date January 2024
Source Almirall, S.A.
Contact Senior Director Regional Medical Affairs
Phone +43 0 15953960
Email medicalat@almirall.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The main aim of this study is to assess the effects of switching from another biologic to tildrakizumab on patient-reported outcomes and to assess psoriasis intensity, patient's quality of life prior and after switching and the individual rationales for switching biologics.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date January 2025
Est. primary completion date January 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Written informed consent. 2. >=18 years of age. 3. Moderate-to-severe plaque psoriasis currently treated with a biologic therapy (TNFa antagonist, IL12/23 antagonist, IL17 antagonist). 4. Switch to tildrakizumab due to: 1. primary or secondary treatment failure (PASI >= 3 or ?PASI < 75 and/or DLQI > 5) 2. adverse events, contraindication, intolerance 3. patient wish (dosing regimen), lack of adherence, or other, including nonmedical reason 5. Treatment with tildrakizumab planned in the frame of clinical practice. Exclusion Criteria: 1. Patient appears to be unwilling or unable to comply with the requirements of the study or who, in the opinion of the Investigator, should not participate in the study. 2. >=3 previous biologic treatments in the last 3 years. 3. Participation in a clinical trial simultaneous to participation in SW-ATCH. 4. Any condition preventing prescription of Tildrakizumab according to the SmPC, including but not restricted to any contraindication or history of hypersensitivity or intolerance. 5. Patient dependent on the Investigator. 6. Previous treatment with Tildrakizumab.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tildrakizumab
As provided in real-world clinical practice.

Locations

Country Name City State
Austria Gesundheitszentrum Citypark Graz Graz Styria

Sponsors (1)

Lead Sponsor Collaborator
Almirall, S.A.

Country where clinical trial is conducted

Austria, 

Outcome

Type Measure Description Time frame Safety issue
Primary Treatment Satisfaction Questionnaire for Medication-11 (TSQM-11) Score TSQM 11-item scale is derived from the TSQM version 1.4, which comprises four domains: global satisfaction, medication effectiveness, convenience, and side effects with scores at each domain ranging from 0 to 100. Higher scores indicating greater satisfaction and lower scores reflecting room for improvement. Baseline, Week 28
Primary World Health Organisation Well-Being Index (WHO-5) Score The WHO-5 consists of 5-items that measure current mental well-being. Each item is rated on 6-point Likert scale, ranging from 0 (at no the time) to 5 (all of the time). The total raw score, ranging from 0 to 25, is multiplied by 4 to give the final score, with 0 representing the worst imaginable well-being and 100 representing the best imaginable well-being. Baseline up to Week 28
Secondary Change from Baseline in absolute Psoriasis Area and Severity Index (PASI) Score The PASI is a measure of psoriasis and psoriatic arthritis severity that will be assessed at baseline and all follow-up visits for participants with psoriasis or psoriatic arthritis. This common clinical measure selects a representative area of psoriasis for each body region. The intensity of redness, thickness, and scaling of the psoriasis is assessed by the clinician. PASI scores range from 0 to 72, with higher scores indicating worse symptoms. Baseline, Week 4, 16 and 28
Secondary Change from Baseline in Physician's Global Assessment (PGA) Score The PGA is an instrument used in clinical trials to rate the severity of psoriasis. It is a 5-point scale measurement ranging from 0 to 4, where 0- clear, 1- almost clear, 2- mild, 3- moderate and 4- severe; based on degree of plaque thickening, scaling and erythema. Baseline, Week 4, 16 and 28
Secondary Change from Baseline in Dermatology Life Quality Index (DLQI) Score The DLQI consists of 10 items addressing the subject's perception of the impact of their skin disease on different aspects of their quality of life. Each item is scored on a 4-point Likert scale (0 = 'not at all / not relevant'; 1 = 'a little'; 2 = 'a lot'; 3 = 'very much'). DLQI scores range from 0 to 30, with higher scores indicating worse quality of life. Baseline, Week 4, 16 and 28
Secondary Number of Participants with Individual Reasons for Initiating Switch to Tildrakizumab At Baseline
See also
  Status Clinical Trial Phase
Completed NCT01194219 - Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis Phase 3
Completed NCT04263610 - Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy Phase 4
Completed NCT02601469 - Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis Phase 2
Completed NCT05600036 - A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis Phase 2
Completed NCT05375955 - A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis. Phase 2
Completed NCT03614078 - A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis Phase 2
Not yet recruiting NCT05036889 - A 16-week Randomized Evaluation of the Impact of Mind.Px Application on Response to Biologic Treatment in Patients Suffering From Plaque Psoriasis Through Clinical Utility and Health Outcomes. N/A
Completed NCT04603027 - A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis Phase 2
Completed NCT03638258 - The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis Phase 2
Completed NCT02881346 - Efficacy and Tolerability of Enstilar® in Daily Practice
Recruiting NCT02611349 - Study to Evaluate the Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis Phase 3
Completed NCT02251678 - Evaluate the Effect of Elimune Capsules Phase 1
Completed NCT01987843 - Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis Phase 2
Terminated NCT01708629 - Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects Phase 3
Completed NCT01230138 - Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis Phase 2
Withdrawn NCT00747032 - To Demonstrate the Superior Efficacy of NYC 0462 Ointment Over That of the Placebo in the Treatment of Plaque Psoriasis Phase 3
Completed NCT00581100 - Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis Phase 4
Suspended NCT01228656 - Effectiveness of Association Mometasone Furoate 0.1% and Salicylic Acid 5% Compared With Mometasone Furoate Phase 2
Completed NCT00540618 - A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis Phase 2
Completed NCT05442788 - A Study of HB0017 in Patients With Moderate to Severe Plaque Psoriasis Phase 1